Shyamali M Singhal, MD
General Surgery · Mountain View
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 28
- 8 carriers
- Office
- 1
On the public record
- Owns El Camino Ambulatory Surgery Center LLC: Accreditation Revoked
Offices
1 location · Shyamali Mallick Singhal MD PHD Inc · 6 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
28 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Singhal’s office at (650) 641-7861 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
28 of 28 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A79445 · Current
Licensed to practise in California · since 2002 · expires 2028-06-30 · Albert Einstein College of Medicine of Yeshiva University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- El Camino Ambulatory Surgery Center LLCAmbulatory Surgery Center · Mountain View, CA.75 owner since 2013 · accredited by AAAHCAccreditation Revoked2 inspections · last 2018-04-05
- El Camino Ambulatory Surgery Center LLCAmbulatory Surgery Center · Mountain View, CAOwner · accredited by JCInitial Accreditation1 inspection, 1 with deficiencies · last 2013-06-10: Requirements Met
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$538,301
Medicare paid this office $538,301 for 280 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 117 | $27,317 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $11,024 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $9,351 | $153 |
| Short return visit (20+ min) | 31 | $8,359 | $59 |
| Removal of muscle and/or tissue, 20.0 sq cm or less | 21 | $8,219 | $137 |
See all 20 services
| Return visit (30+ min) | 117 | $27,317 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 42 | $11,024 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $9,351 | $153 |
| Short return visit (20+ min) | 31 | $8,359 | $59 |
| Removal of muscle and/or tissue, 20.0 sq cm or less | 21 | $8,219 | $137 |
| Removal of skin and tissue, 20.0 sq cm or less | 32 | $8,087 | $126 |
| Removal of skin and tissue, 20.0 sq cm or less | 38 | $7,424 | $53 |
| Short return visit (20+ min) | 29 | $6,875 | $84 |
| Long return visit (40+ min) | 31 | $5,284 | $165 |
| New patient visit (60+ min) | 26 | $5,214 | $201 |
| Return visit (30+ min) | 28 | $4,716 | $87 |
| New patient visit (45+ min) | 31 | $4,530 | $146 |
| Application of chemical to stop tissue regrowth in wound | 19 | $3,815 | $60 |
| Biopsy or removal of deep lymph nodes of underarm | 12 | $3,188 | $266 |
| New patient visit (45+ min) | 13 | $1,549 | $119 |
| Imaging of lymph nodes during surgery | 12 | $1,514 | $116 |
| New patient visit (30+ min) | 14 | $1,487 | $106 |
| Application of chemical to stop tissue regrowth in wound | 26 | $1,463 | $20 |
| New patient visit (30+ min) | 17 | $1,244 | $73 |
| Emergency department visit with low level of medical decision making | 11 | $659 | $60 |
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Hernia repair (minimally invasive) | 1-10 | None |
| Mastectomy | 12 | More than 67% of doctors who do this |
| Melanoma (skin cancer) excision | 11 | More than 64% of doctors who do this |
| Removal of skin lesions | 11 | More than 58% of doctors who do this |
| Removal of tissue | 70 | More than 82% of doctors who do this |
| Skin biopsy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Who their Medicare patients are
280 Original Medicare patients in 2024. Average age 78 · Women 65% · Also on Medicaid 18% · Health risk score 1.65. At or below the middle of the specialty; the typical general surgery clinician is at 1.69.
Conditions among them: High blood pressure 75% · Cancer 45% · Diabetes 33% · Chronic kidney disease 32% · Coronary heart disease 26% · Depression 24% · Heart failure 22% · Atrial fibrillation 22% · Dementia 14% · COPD 12% · Stroke 9%.
The office billed $1,504,090, Medicare allowed $678,566 and paid $538,301; for 1,984 services of 80 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 280 | 1,984 | 78 | 1.65 | $1,504,090 | $538,301 |
| 2023 | 173 | 634 | 78 | 1.37 | $479,319 | $118,738 |
| 2022 | 135 | 440 | 78 | 1.37 | $292,668 | $58,033 |
| 2021 | 133 | 581 | 77 | 1.95 | $359,307 | $77,885 |
| 2020 | 89 | 159 | 77 | 1.20 | $182,614 | $31,310 |
| 2019 | 126 | 245 | 76 | 1.42 | $246,839 | $53,590 |
| 2018 | 127 | 286 | 77 | 1.24 | $265,432 | $68,243 |
| 2017 | 103 | 224 | 76 | 1.14 | $90,023 | $50,772 |
| 2016 | 108 | 228 | 75 | 1.12 | $119,755 | $44,267 |
| 2015 | 110 | 236 | 75 | 1.07 | $148,264 | $40,139 |
| 2014 | 106 | 174 | 75 | 1.28 | $120,850 | $31,224 |
| 2013 | 95 | 203 | 75 | 1.21 | $170,926 | $40,756 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Return visit (30+ min) | 71 | $14,295 | $118 |
| New patient visit (60+ min) | 25 | $4,997 | $200 |
| New patient visit (45+ min) | 25 | $3,931 | $157 |
| Biopsy or removal of deep lymph nodes of underarm | 13 | $3,495 | $269 |
| Short return visit (20+ min) | 34 | $3,277 | $80 |
| Short return visit (20+ min) | 17 | $2,444 | $60 |
| Removal of skin and tissue, 20.0 sq cm or less | 14 | $2,299 | $51 |
| Imaging of lymph nodes during surgery | 12 | $1,509 | $126 |
2022: 5 services
| Return visit (30+ min) | 49 | $8,367 | $115 |
| New patient visit (45+ min) | 21 | $2,627 | $125 |
| Short return visit (20+ min) | 19 | $2,126 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,821 | $121 |
| New patient visit (30+ min) | 13 | $977 | $75 |
2021: 5 services
| Return visit (30+ min) | 41 | $8,249 | $120 |
| New patient visit (60+ min) | 17 | $3,276 | $193 |
| Short return visit (20+ min) | 12 | $2,443 | $72 |
| Short return visit | 17 | $1,892 | $33 |
| New patient visit (45+ min) | 12 | $1,771 | $148 |
2020: 3 services
| Return visit (30+ min) | 35 | $4,906 | $102 |
| New patient visit (60+ min) | 20 | $3,898 | $195 |
| Long return visit (40+ min) | 19 | $2,587 | $118 |
2019: 4 services
| Long return visit (40+ min) | 65 | $11,787 | $128 |
| New patient visit (60+ min) | 33 | $6,261 | $190 |
| Return visit (30+ min) | 25 | $2,880 | $103 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,351 | $181 |
2018: 3 services
| Long return visit (40+ min) | 63 | $12,784 | $130 |
| New patient visit (60+ min) | 55 | $10,345 | $188 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $3,086 | $182 |
2017: 4 services
| Long return visit (40+ min) | 37 | $6,149 | $131 |
| New patient visit (60+ min) | 30 | $5,110 | $170 |
| Return visit (30+ min) | 39 | $4,759 | $92 |
| Biopsy or removal of deep lymph nodes of underarm | 11 | $3,319 | $277 |
2016: 4 services
| New patient visit (60+ min) | 37 | $6,977 | $189 |
| Return visit (30+ min) | 43 | $5,303 | $91 |
| Long return visit (40+ min) | 22 | $3,375 | $125 |
| Short return visit (20+ min) | 14 | $1,098 | $65 |
2015: 3 services
| Return visit (30+ min) | 51 | $7,586 | $93 |
| New patient visit (60+ min) | 29 | $5,288 | $182 |
| Long return visit (40+ min) | 12 | $1,978 | $124 |
2014: 3 services
| Return visit (30+ min) | 49 | $6,504 | $93 |
| New patient visit (60+ min) | 20 | $3,752 | $188 |
| New patient visit (45+ min) | 13 | $1,858 | $143 |
2013: 2 services
| Return visit (30+ min) | 61 | $9,159 | $91 |
| New patient visit (60+ min) | 23 | $4,294 | $187 |
Drugs they prescribed that Part D paid
$783
Pharmacies billed $783 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 44% of their Part D prescriptions (16 of 36) in 2024. Too few prescriptions to compare fairly with other clinicians.
33 generic and fewer than 11 brand-name prescriptions · $783 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Hydrocodone-Acetaminophen | 15 | $46 | $3 |
Year by year
| 2024 | 36 | 26 | 44% (16) | None | $783 |
| 2023 | 83 | 51 | 46% (38) | 19% | $7,900 |
| 2022 | 72 | 38 | 36% (26) | None | $892 |
| 2021 | 73 | 37 | 51% (37) | None | $4,145 |
| 2020 | 38 | 20 | 66% (25) | None | $1,120 |
| 2019 | 40 | 32 | 70% (28) | 0% | $324 |
| 2018 | 48 | 34 | 56% (27) | None | $573 |
| 2017 | 51 | 31 | 61% (31) | None | $1,035 |
| 2016 | 48 | 33 | 63% (30) | None | $698 |
| 2015 | 53 | 26 | 81% (43) | None | $1,427 |
| 2014 | 34 | 25 | 59% (20) | None | $829 |
| 2013 | 56 | 19 | 41% (23) | None | $3,036 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Hydrocodone-Acetaminophen | 32 | $136 | $4 |
2022: 2 drugs
| Valsartan-Hydrochlorothiazide | 11 | $189 | $17 |
| Hydrocodone-Acetaminophen | 22 | $159 | $7 |
2021: 1 drug
| Hydrocodone-Acetaminophen | 30 | $284 | $9 |
2020: 1 drug
| Hydrocodone-Acetaminophen | 18 | $80 | $4 |
2019: 1 drug
| Hydrocodone-Acetaminophen | 26 | $115 | $4 |
2018: 1 drug
| Hydrocodone-Acetaminophen | 27 | $171 | $6 |
2017: 1 drug
| Hydrocodone-Acetaminophen | 26 | $245 | $9 |
2016: 1 drug
| Hydrocodone-Acetaminophen | 26 | $415 | $16 |
2015: 1 drug
| Hydrocodone-Acetaminophen | 30 | $404 | $13 |
2014: 1 drug
| Hydrocodone-Acetaminophen | 15 | $428 | $29 |
2013: 1 drug
| Hydrocodone-Acetaminophen | 16 | $78 | $5 |
Money from drug and device companies
$2,959 in 2025
| 2025 | 7 | 15 | $1,250 | $2,959 |
| 2024 | 8 | 13 | $825 | $1,207 |
| 2023 | 11 | 19 | None | $485 |
| 2022 | 4 | 13 | None | $305 |
| 2021 | 8 | 13 | None | $514 |
| 2020 | 10 | 12 | None | $281 |
| 2019 | 18 | 45 | None | $893 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Histosonics | None | $1,505 | 2 payments
|
| Stryker | None | $1,250 | 1 payment
|
| Smith+Nephew | Collagenase Santyl | $109 | 3 payments
|
| Blue Earth Diagnostics | Posluma | $38 | 1 payment
|
| Biotissue Holdings | None | $29 | 1 payment
|
| Kerecis | Kerecis Surgiclose | $15 | 1 payment
|
See all 10 published payments
| Exact Sciences | Meals · 2025-11-20 | None | $14 |
| Histosonics | Meals · 2025-10-09 | None | $225 |
| Histosonics | Travel · 2025-10-08 | None | $1,280 |
| Stryker | Consulting · 2025-07-29 | None | $1,250 |
| Smith+Nephew | Meals · 2025-06-13 | Collagenase Santyl | $37 |
| Smith+Nephew | Meals · 2025-03-31 | Stravix | $46 |
| Biotissue Holdings | Meals · 2025-03-11 | None | $29 |
| Smith+Nephew | Meals · 2025-02-28 | Collagenase Santyl | $26 |
| Kerecis | Meals · 2025-02-06 | Kerecis Surgiclose | $15 |
| Blue Earth Diagnostics | Meals · 2025-02-06 | Posluma | $38 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,207
| Stryker | None | $825 | 1 payment
|
| Kub Technologies | Mozart | $122 | 1 payment
|
| Smith+Nephew | Collagenase Santyl | $77 | 3 payments
|
| Biotissue Holdings | None | $45 | 2 payments
|
| Histosonics | None | $36 | 1 payment
|
| Integra LifeSciences | Integra | $36 | 2 payments
|
| Organogenesis | None | $36 | 2 payments
|
| Solventum | Activ.A.C. | $30 | 1 payment
|
2023: $485
| Organogenesis | Puraply | $233 | 8 payments
|
| Lexington Medical | Aeon Endostapler & Echelon Flex Powered Stapler | $45 | 1 payment
|
| Smith+Nephew | Grafix | $41 | 2 payments
|
| Coloplast | Sensura Mio | $29 | 1 payment
|
| Elucent Medical | None | $28 | 1 payment
|
| Musculoskeletal Transplant Foundation | None | $21 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $19 | 1 payment
|
| Integra LifeSciences | Codman Certas | $18 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $16 | 1 payment
|
| Molnlycke Health Care US | Mepilex Border Flex | $14 | 1 payment
|
2022: $305
| Merit Medical Systems | Savi Scout | $111 | 3 payments
|
| Myriad Genetic Laboratories | Myrisk | $87 | 5 payments
|
| Smith+Nephew | Grafix Pl | $56 | 3 payments
|
| Organogenesis | Puraply | $51 | 2 payments
|
2021: $514
| Heron Therapeutics | Zynrelef | $123 | 1 payment
|
| Merit Medical Systems | Savi Scout | $97 | 2 payments
|
| Organogenesis | Puraply Antimicrobial | $83 | 3 payments
|
| Integra LifeSciences | Cytal | $74 | 2 payments
|
| Smith+Nephew | Oasis | $53 | 2 payments
|
| PolarityTE | None | $35 | 1 payment
|
| AbbVie | Dalvance | $26 | 1 payment
|
| Myriad Genetic Laboratories | Myrisk | $23 | 1 payment
|
2020: $281
| Acell | None | $88 | 3 payments
|
| Seagen | Adcetris | $30 | 1 payment
|
| Smith+Nephew | Stravix | $27 | 1 payment
|
| Incyte | Jakafi | $23 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $22 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $20 | 1 payment
|
| Novartis Pharmaceuticals | Tasigna | $20 | 1 payment
|
| Janssen Biotech | Darzalex | $18 | 1 payment
|
| Celgene | Pomalyst | $17 | 1 payment
|
| Foundation Medicine | Foundationone | $16 | 1 payment
|
2019: $893
| Lilly USA | Alimta | $135 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $108 | 4 payments
|
| Novartis Pharmaceuticals | Votrient | $98 | 5 payments
|
| Bayer HealthCare Pharmaceuticals | Xofigo | $57 | 3 payments
|
| Acell | None | $56 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Empliciti | $55 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $54 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $53 | 3 payments
|
| Amgen | Nplate | $53 | 2 payments
|
| AngioDynamics | None | $45 | 1 payment
|
| Celgene | Revlimid | $32 | 2 payments
|
| Incyte | Jakafi | $30 | 2 payments
|
| Rigel Pharmaceuticals | Tavalisse | $26 | 1 payment
|
| Janssen Biotech | Darzalex | $24 | 1 payment
|
| Tesaro | Zejula | $23 | 1 payment
|
| Eisai | Halaven | $16 | 1 payment
|
| Smith+Nephew | Stravix | $16 | 1 payment
|
| Clovis Oncology | Rubraca | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · Roche Cancer Screening Collection Study · 2024 | Their institution | $10,520 |
Professional record
- NPI
- 1992769939
- Licence
- CA A79445California A79445: Current · expires 2028-06-30
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Surgery (208600000X); Surgical oncology (2086X0206X)
- Mailing address
- 2500 Hospital Dr Ste 15-1, Mountain View, CA, 94040
- NPI first listed
- 2006-04-14
- NPI last updated
- 2023-10-19
- NPI record certified
- 2023-09-27
This is when the NPI record was last certified, not a medical board exam.